carboplatin + nedaplatin

Carboplatin + nedaplatin is a combination of two platinum-based chemotherapeutic agents used in oncology. Both drugs are second-generation platinum analogues that exert their antineoplastic effects primarily through the formation of DNA crosslinks, leading to inhibition of DNA replication and transcription, and ultimately inducing apoptosis in rapidly dividing tumor cells. Carboplatin is widely used for ovarian, lung, head and neck cancers, while nedaplatin has similar indications but with reduced nephrotoxicity compared to cisplatin. This combination may be considered in clinical settings where sequential or alternative platinum therapy is needed due to toxicity or resistance concerns[6][1][4]. The use of both agents together (as opposed to either alone or with other cytotoxics) is not standard but may be explored in research or specific clinical scenarios.